Christopher Male, co-founder of the Autism Impact Fund, invests in early-to-growth-stage (seed to Series B) for-profit. See sector focus and contact routes.
Christopher Male, co-founder of the Autism Impact Fund, invests in early-to-growth-stage (seed to Series B) for-profit companies developing diagnostics, precision therapeutics, digital health, and AI-driven care delivery for autism and related neurodivergent conditions. His distinctive thesis leverages venture capital to "revolutionize the status quo" in autism diagnosis and treatment, intentionally focusing on commercial entities to avoid overlap with nonprofits. Notable portfolio companies include Floreo (AI-driven virtual reality therapies), Joshin (digital care platform), SpectrumAi (autism care technology), Axial (gut-restricted small molecules), and BioROSA (autism biomarkers), with two successful exits recorded in Joshin and SpectrumAi.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Winter Park.
Investors like Christopher Male · Full investor directory · Investor access · Company funding database